Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Pituitary Tumor Removal
NCT03132259Phase 4Unknown
- Sponsor
- Mahidol University
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in pituitary tumor, sponsored by Mahidol University. Primary endpoint: Hemodynamic stability (Heart Rate and Blood Pressure) at 24 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
pituitary tumor
Beyond the preview
Go deeper on NCT03132259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132259.